摘要
目的观察长春胺注射液对原发性缺血性视神经视网膜脉络膜病变的疗效和安全性。方法采用随机对照方法,将原发性缺血性视神经视网膜脉络膜病变患者60例随机分为对照组(30例)、治疗组(30例),对照组采用妥拉唑林注射液25 mg患眼颞侧颞浅动脉旁皮下注射,治疗组采用妥拉唑林注射液25 mg患眼颞侧颞浅动脉旁皮下注射同时应用长春胺注射液20 mg+0.9%NS250 ml静滴,1次/d,疗程为20 d。结果有效率治疗组为76.7%,对照组为40.0%,两者比较,差异有显著统计学意义(U=203.5,P<0.01)。治疗组除3例患者有短暂恶心,头昏,2例有短暂腹痛外,与对照组均无严重不良反应。结论长春胺对原发性缺血性视神经视网膜脉络膜病变的治疗是有效和安全的。
Objective To investigate the treatment effect of vinpocetine injection on primary ischemic optic neuropathy and choroidoretinopathy and its safety. Methods A randomized and controlled study was applied to 60 patients with primary ischemic optic neuropathy and choroidoretinopathy. The patients were assigned into two groups at random： 30 patients in control group and the other 30 ones in trial group. Vinpooytine （2 ml） was injected to the trial group once per day. while tolazoline （25 mg） was given in the same way to the control group for 20 days. Visual acuity, visual field and fundus condition were examined so that the effect of treatment could be evaluated. The safety of the treatment was studied via intraocular pressure, blood pressure, electrocardiogram, routine blood and urine examination, and blood tests for renal and liver function. The main subjects of the two groups before treatment were comparable （ P 〉 0.05 ）. Results The difference in effective rate between trial group （ 76.7 % ） and control group （40.0%） was significant （P 〈0.01 ）. There were a few of side effects in some patients and the parameters related to the safety had no significant change before and after treatment. Conclusion Vinpocetine is a safe and effective drug to treat primary ischemic optic neuropathy and choroidoretinopathy.
出处
《临床军医杂志》
CAS
2008年第2期231-232,共2页
Clinical Journal of Medical Officers
